Company Performance Metrics
Biocentaur develops and provides genetic testing services focused on medical genetics and molecular diagnostics. The company offers qPCR- and DNA sequencing-based assays that help clinicians assess inherited disease risk, detect viral and bacterial pathogens, and understand patient-specific treatment responses. Its PrediSpot test evaluates genetic
predisposition to chronic non-cancerous conditions, while PrimeSpot detects Lyme disease, chronic fatigue syndrome and other viral infections from blood samples. The PaldiSpot test characterizes multiple Borrelia, Babesia and Bartonella strains to support targeted Lyme disease management. Biocentaur’s SNPs test analyzes single-nucleotide polymorphisms to inform pharmacogenomic decisions for drugs such as antibiotics, anticoagulants and anti-inflammatories. These services are used by healthcare professionals and eligible adults to support diagnosis, therapy selection and personalized care planning.
